BofA/Merrill Lynch Downgrades BioCryst Pharma (BCRX) to Underperform
Tweet Send to a Friend
BofA/Merrill Lynch downgraded BioCryst Pharma (NASDAQ: BCRX) from Neutral to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
